^
Association details:
| Biomarker: | IL6-L |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
Excerpt:
Low pIL6 at baseline was significantly associated with improved response to sunitinib (Fisher's exact test, p < 0.01)…. low pIL6 at baseline was significantly associated with improved PFS (log rank, = 0.04 …Forty-six patients with metastatic or non-resectable ccRCC treated with sunitinib...
DOI:
10.1016/j.ctarc.2019.100127
